Nav: Home

MTHFD2 mitochondrial metabolic enzyme maintains cancer stem-like cells

February 21, 2019

An increase in the incidence and mortality rate of cancer has been noted worldwide, especially for lung cancer. Many patients with lung adenocarcinoma harbor mutations in epidermal growth factor receptor (EGFR), and initially show a good response to molecular target drugs, such as gefitinib, which inhibits the EGFR tyrosine kinase. However, recurrence inevitably occurs within a few years because of acquired drug resistance, leading to poor prognosis. Despite the development of new generations of molecular targeted drugs, recurrence and acquired drug resistance remain problematic.

Emerging evidence suggests that cancer stem-cells (CSCs) are responsible for tumor recurrence and drug resistance. Tumor tissues comprise heterogeneous cell types including CSCs and their differentiated progeny, as observed in normal tissues derived from tissue-specific stem cells. Most cancer therapies, such as conventional chemotherapy, radiotherapy, and molecular target drugs, target rapidly proliferating differentiated cancer cells, but not CSCs. It is thought that cancer cells with stem-like properties continue to survive after treatment, and a fraction of these cells exhibit the ability to re-divide after years, causing recurrence. Thus, targeted therapies against CSCs and their daughter cells are important for tumor eradication; however, this is still an area of unmet medical need. To establish such therapies, it is important to investigate the molecular mechanisms that determine how CSCs are maintained in cancer tissues. Although it is believed that various metabolic pathways are activated in cancer cells, the specific metabolic mechanisms in CSCs remain largely unclear.

One-carbon (1C) metabolism incorporates carbons as building blocks of purine and pyrimidine that are used for DNA replication and RNA transcription, and thus plays an important role in cell proliferation (Figure). In the mitochondria, methylenetetrahydrofolate dehydrogenase (MTHFD2), an enzyme involved in 1C metabolism, is strongly expressed in cancer cells, while it is scarcely expressed in normal cells. MTHFD2 is required for cancer cell proliferation. Active MTHFD2 consumes 5-aminoimidazole carboxamide ribonucleotide (AICAR), an intermediate of the purine synthesis pathway, to produce IMP, a purine nucleotide.

We discovered that it is essential to continuously consume AICAR and reduce its concentration in cancer cells to low levels for the maintenance of CSCs. Active MTHFD2 is critical for this mechanism. Therefore, MTHFD2-mediated mitochondrial 1C metabolism appears critical for the survival of CSCs and resistance to drugs including gefitinib through consumption of AICAR, leading to depletion of the intracellular pool of AICAR. Because CSCs are dependent on MTHFD2, therapies targeting MTHFD2 may eradicate tumors and prevent recurrence.

Kanazawa University

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".